Designation of Rufinamide as an orphan drug - Eisai Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the provision of therapeutic goods in Australia, ensuring their safety, quality, and efficacy. This legislation was introduced to address the need for a comprehensive framework governing the importation, supply, and advertising of therapeutic products within the country. The Act was passed by the Commonwealth Parliament, aiming to protect public health by controlling the therapeutic goods market. The designation of rufinamide (TBA) as an orphan drug under the Therapeutic Goods Regulations 1990 is one such measure, aimed at encouraging the development and availability of treatments for rare diseases or conditions with limited patient populations. By designating rufinamide for the treatment of seizures associated with Lennox-Gastaut syndrome, the Therapeutic Goods Administration recognises the importance of providing therapeutic options for patients affected by this rare and severe form of epilepsy.

Scope and Application

The Therapeutic Goods Act 1989, as amended, encompasses a broad scope of activities and entities related to therapeutic goods in Australia. This Act applies to the regulation and control of therapeutic goods, including medicines, medical devices, and blood and blood components. The legislation primarily applies to entities such as manufacturers, importers, and suppliers of therapeutic goods, as well as to individuals who engage in activities such as advertising, supplying, or conducting research related to these goods. The Act's jurisdictional reach extends across the Commonwealth, meaning it applies nationally and is enforced by the Therapeutic Goods Administration (TGA), a regulatory body under the Department of Health. Notably, the Act provides for certain exclusions and exemptions, such as therapeutic goods for personal use and research, but these are narrowly defined to ensure the primary objective of protecting public health is met. Additionally, the application of the Act can be extended or restricted through subordinate instruments, such as regulations and standards, which provide more detailed provisions and requirements for specific types of therapeutic goods or activities.

Key Provisions

The key provision of this legislative instrument (C2016G01319) is the designation of rufinamide (TBA) as an orphan drug under section 16J of the Therapeutic Goods Regulations 1990 (Regulations) (paragraph 1). This designation is made by Dr. Anthony Gill, the Delegate of the Secretary, on behalf of the Secretary for the purposes of section 16J of the Regulations. The orphan drug designation applies specifically to the treatment of seizures associated with Lennox-Gastaut syndrome, and the approved dose forms are tablets and oral suspension (paragraph 2). The sponsor of rufinamide (TBA) is Eisai Australia Pty. Ltd. (paragraph 3). The Therapeutic Goods Act 1989 (Act) and the Regulations impose several obligations and requirements on the parties involved. The Act ensures that therapeutic goods, including orphan drugs, meet specific safety, quality, and efficacy standards before they can be supplied in Australia. The Regulations further detail the processes and criteria for the designation of orphan drugs, including the need for scientific evidence supporting the orphan drug status and the therapeutic benefits of the drug for the targeted condition (Regulation 16J). The sponsor, in this case, Eisai Australia Pty. Ltd., must comply with these regulatory requirements, including providing necessary documentation and data to support the orphan drug designation (paragraph 4). Breach of the provisions of the Act or Regulations may lead to various consequences, including civil and criminal penalties. Under the Act, serious and repeated breaches can result in substantial fines and, in some cases, imprisonment for individuals. For corporate entities, the penalties can be significantly higher. The specific penalties are outlined in the Act, with maximum penalties varying based on the nature and severity of the breach (paragraph 5). Furthermore, failure to comply with the orphan drug designation requirements could result in the refusal of market authorisation for rufinamide (TBA) in Australia, which would prevent its supply and use for the intended therapeutic purpose (paragraph 6). The Therapeutic Goods Regulations 1990 also establish a framework for the oversight and monitoring of therapeutic goods, including orphan drugs. This includes provisions for post-market surveillance, reporting of adverse events, and the requirement for sponsors to maintain records and documentation to demonstrate compliance with regulatory standards (paragraph 7). These obligations are crucial to ensuring the continued safety and efficacy of therapeutic goods supplied in the Australian market. The Regulations also provide mechanisms for the Therapeutic Goods Administration (TGA) to take enforcement actions, including product recalls and legal proceedings, against non-compliant sponsors or manufacturers (paragraph 8). In summary, the legislative instrument (C2016G01319) designates rufinamide (TBA) as an orphan drug for the treatment of seizures associated with Lennox-Gastaut syndrome. This designation is made under the authority of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990, which impose obligations on the sponsor, Eisai Australia Pty. Ltd., to comply with specific regulatory requirements. Breach of these provisions can result in significant civil and criminal penalties, and failure to meet the orphan drug designation criteria could prevent the supply of rufinamide (TBA) in Australia. The Regulations also establish a framework for ongoing oversight and monitoring to ensure the safety and efficacy of therapeutic goods supplied in the Australian market (paragraph 9).